2022-03-18 |
1 |
Complaint |
Therapeutics Inc.. (Attachments: # 1 Exhibit A-US 8,058,069, # 2 Exhibit B-US 8,492,359, # 3 Exhibit C-US …2022
7 August 2023
1:22-cv-02229
830 Patent
None
District Court, S.D. New York |
External link to document |
2022-09-06 |
42 |
Amended Complaint |
Exhibit A-US Patent No. 8,058,069, # 3 Exhibit B-US Patent No. 8,492,359, # 4 Exhibit C-US Patent No. 8,822,668…Exhibit D-US Patent No. 9,006,417, # 6 Exhibit E-US Patent No. 9,364,435, # 7 Exhibit F-US Patent No. 9,404,127…Exhibit G-US Patent No. 9,504,651, # 9 Exhibit H-US Patent No. 9,518,272, # 10 Exhibit I-US Patent No. 11,141,378…2022
7 August 2023
1:22-cv-02229
830 Patent
None
District Court, S.D. New York |
External link to document |
2022-10-04 |
44 |
Memorandum of Law in Support of Motion |
See, e.g., Dkt. 1-1 (U.S. Patent No. 8,058,069, claim 1). All the
patents require both a nucleic acid…for two patents, the ’502
patent and the ’402 patent mentioned above. Addressing each patent in turn,…multiple patents. A product infringing the patentee’s
patent might therefore also apply the patents of third…claim
of nine patents owned by Arbutus and licensed to Genevant (“Defendants’ Patents”) and that
Defendants…2018, BNT licensed Defendants’ Patents from Genevant, among other
patents, in connection with BNT’s development |
External link to document |
2023-08-01 |
78 |
Exhibit A - NJ Counterclaims |
vaccine may infringe Arbutus patents, including at least U.S. Patent Nos. 8,058,069, 8,492,359,
8,822,668… Application issued as U.S. Pat. No. 8,058,069 (the “’069 Patent”) on November 15, 2011.
…Office issued the ’651
Patent, ’359 Patent, ’378 Patent, ’320 Patent, and ’098 Patent, but deny that the …“’708 Patent”), 8,329,070 (the “’070 Patent”), and 9,492,386 (the “’386 Patent”).
Each patent claims…manufacturing them.
Among those patents are the Asserted Patents:
a. U.S. Patent No. 9,504,651, “Lipid |
External link to document |